Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
Business & Industry
- The Merck Accelerator Program 2019
- Novo Nordisk announces plans to transform its approach to Research & Development
- World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime
- The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease
- Abbott is named global industry leader in sustainability for the sixth consecutive year on the Dow Jones Sustainability Index (DJSI)
Research & Development
- Discovery could explain failed clinical trials for Alzheimer's, and provide a solution
- Aspirin found not to prolong healthy aging
- Clinical gene discovery program solves 30 medical mysteries
- Dietary fiber reduces brain inflammation during aging
- Drug for pancreatic cancer developed by college of pharmacy researchers
- Regrowing dental tissue with stem cells from baby teeth
- Study links widely-used drug azathioprine to skin cancers
Conferences & Events
- Social Media in the Pharmaceutical Industry Conference 2019
- Lyophilization USA Conference 2018
- SMi presents the 13th annual industry leading conference: Cold Chain Distribution
- Orphan Drugs and Rare Diseases Conference 2018
- Immuno-Oncology Conference 2018
- Ophthalmic Drugs Conference 2018
- SMi presents the launch of Cell & Gene Therapy 2018
Regulatory Affairs
- FDA approves new kind of treatment for hairy cell leukemia
- FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease
- FDA approves treatment for two rare types of non-Hodgkin lymphoma
- FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
- FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency